Group | Antimicrobials | Resistance to antimicrobial agents by year | a P-values of CAT Test | |||||
---|---|---|---|---|---|---|---|---|
2007 | 2008 | 2009 | 2010 | 2011 | 2012 | |||
β-lactams | Penicillin | 75.0 (6/8) | 80.0 (12/15) | 63.6 (7/11) | 50.0 (5/10) | 50.0 (3/6) | 50.0 (3/6) | 0.089 |
Ampicillin | 75.0 (6/8) | 80.0 (12/15) | 63.6 (7/11) | 60.0 (6/10) | 50.0 (3/6) | 50.0 (3/6) | 0.124 | |
Cephalothin | 25.0 (2/8) | 6.7 (1/15) | 9.1 (1/11) | 10.0 (1/10) | 0.0 (0/6) | 0.0 (0/6) | 0.181 | |
Aminoglycosides | Amikacin | 0.0 (0/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.258 |
Gentamicin | 12.5 (1/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.098 | |
Kanamycin | 25.0 (2/8) | 26.7 (4/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 0.0 (0/6) | 0.017 | |
Tetracyclines | Doxycycline | 37.5 (3/8) | 26.7 (4/15) | 36.4 (4/11) | 20.0 (2/10) | 0.0 (0/6) | 0.0 (0/6) | 0.041 |
Fluoroquinolones | Enrofloxacin | 0.0 (0/8) | 6.7 (1/15) | 0.0 (0/11) | 0.0 (0/10) | 16.7 (1/6) | 50.0 (3/6) | 0.005 |
Orbifloxacin | 12.5 (1/8) | 20.0 (3/15) | 9.1 (1/11) | 0.0 (0/10) | 16.7 (1/6) | 33.3 (2/6) | 0.718 | |
Potentiated-sulfas | Co-trimoxazoleb | 37.5 (3/8) | 33.3 (5/15) | 27.3 (3/11) | 10.0 (1/10) | 0.0 (0/6) | 16.7 (1/6) | 0.067 |
Amphenicols | Chloramphenicol | 33.3 (1/3) | 20.0 (3/15) | 9.1 (1/11) | 10.0 (1/10) | 40.0 (2/5) | 33.3 (2/6) | 0.552 |
Macrolides | Tylosin | 37.5 (3/8) | 33.3 (5/15) | 0.0 (0/11) | 10.0 (1/10) | 0.0 (0/6) | 0.0 (0/6) | 0.008 |
Aminoglycoside-lincosamides | Lincospectinc | 37.5 (3/8) | 80.0 (12/15) | 54.6 (6/11) | 70.0 (7/10) | 50.0 (3/6) | 83.3 (5/6) | 0.478 |
Lincosamides | Clindamycin | 50.0 (4/8) | 60.0 (9/15) | 45.5 (5/11) | 60.0 (6/10) | 50.0 (3/6) | 33.3 (2/6) | 0.552 |
Others | Amoxicillin/clavulanic acid | 37.5 (3/8) | 33.3 (5/15) | 9.1 (1/11) | 0.0 (0/10) | 0.0 (0/6) | 16.7 (1/6) | 0.032 |